SCM
JBIO

Sterling Capital Management’s Jade Biosciences JBIO Stock Holding History

Sterling Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53K Sell
114
-942
-89% -$19.6K ﹤0.01% 2925
2026
Q1 		$14.8K Sell
1,056
-1,611
-60% -$23.3K ﹤0.01% 2164
2025
Q4 		$41.2K Buy
2,667
+429
+19% +$5.03K ﹤0.01% 1874
2025
Q3 		$19.3K Buy
2,238
+1,362
+155% +$11.1K ﹤0.01% 2167
2025
Q2 		$8.75K Buy
+876
New +$29.8K ﹤0.01% 2217
2025
Q1 		– Hold
0
– – – 3192
2024
Q4 		– Hold
0
– – – 3223
2024
Q3 		– Hold
0
– – – 3248

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's JBIO Position: Q2 2026 in Review

Sterling Capital Management reduced its Jade Biosciences (JBIO) stake by 89% in Q2 2026, selling an estimated $19.6K and leaving 114 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #2925.

Sterling Capital Management first reported a position in JBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $41.2K in Q4 2025. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Sterling Capital Management held 114 shares of Jade Biosciences worth $2.53K as of Q2 2026.
  • Sterling Capital Management sold 942 Jade Biosciences shares in Q2 2026, an estimated $19.6K.
  • Jade Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2925 holding.
  • Sterling Capital Management first reported a position in Jade Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Jade Biosciences position peaked at $41.2K in Q4 2025.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.